Patent Owner’s Statements Made During Inter Partes Review Constitute Disclaimer, Leading to Summary Judgment of Noninfringement

Nov 21, 2018

Reading Time : 1 min

In the litigation, patent owner Radware and accused infringer F5 Network, each filed summary judgment motions on the issue of infringement, which centered on the construction of the claim term “decision function.” Both parties agreed to construe the term as “function used to decide which data route is selected based on its parameters;” however, the court determined that the agreed-upon definition was ambiguous because “its” could refer to either “data route” or “function.” To resolve the conflict, the court relied on Radware’s argument during IPR that “its” referred to “data route” parameters to conclude that—as a matter of law—the input for “decision function” was limited to data route parameters. The court held that Radware could not broaden the meaning of the term in view of its IPR statements.

Relying on Federal Circuit law, the court explained that “statements made by the patent owner during inter partes review put the public on notice of how the patent owner views its patent.” The court held that “[e]ven if the PTAB may not have expressly adopted Radware’s interpretation, the public is still entitled to rely on it.” Accordingly, the court denied Radware’s motion for summary judgment and granted F5 Network’s summary judgment motion of noninfringement.

Practice Tip:

When presenting arguments in an IPR proceeding to distinguish prior art, patent owners must be cognizant of the potential disclaimer effects of their arguments on ongoing or future litigation. In district court litigation, patent owners will be bound by their IPR arguments, which may foreclose certain infringement theories. Further, whether the PTAB relies on such arguments is immaterial to whether the arguments serve as a disclaimer.

F5 Networks, Inc. v. Radware, Inc., No. 17-cv-03166-VC, slip op. (N.D. Cal. Nov. 19, 2018).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.